Second Sight Medical Products, Inc. (NASDAQ:EYES – Get Rating) Director Gregg Williams acquired 387,044 shares of the firm’s stock in a transaction that occurred on Wednesday, May 18th. The stock was acquired at an average price of $1.66 per share, for a total transaction of $642,493.04. Following the completion of the transaction, the director now directly owns 10,277,853 shares in the company, valued at $17,061,235.98. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.
NASDAQ:EYES traded up $0.15 on Friday, reaching $2.00. The stock had a trading volume of 603,013 shares, compared to its average volume of 486,634. The firm’s fifty day moving average is $1.47 and its two-hundred day moving average is $1.65. Second Sight Medical Products, Inc. has a 12-month low of $1.14 and a 12-month high of $7.64.
Second Sight Medical Products (NASDAQ:EYES – Get Rating) last released its earnings results on Monday, March 28th. The medical device company reported ($0.02) earnings per share (EPS) for the quarter.
A number of large investors have recently added to or reduced their stakes in the business. Bank of America Corp DE lifted its holdings in shares of Second Sight Medical Products by 497.5% during the 2nd quarter. Bank of America Corp DE now owns 9,237 shares of the medical device company’s stock worth $46,000 after acquiring an additional 7,691 shares during the period. Goldman Sachs Group Inc. lifted its holdings in shares of Second Sight Medical Products by 37.6% during the 4th quarter. Goldman Sachs Group Inc. now owns 33,950 shares of the medical device company’s stock worth $55,000 after acquiring an additional 9,272 shares during the period. LPL Financial LLC lifted its holdings in shares of Second Sight Medical Products by 93.0% during the 4th quarter. LPL Financial LLC now owns 20,698 shares of the medical device company’s stock worth $34,000 after acquiring an additional 9,971 shares during the period. Two Sigma Advisers LP purchased a new position in shares of Second Sight Medical Products during the 3rd quarter worth about $44,000. Finally, Millennium Management LLC purchased a new position in shares of Second Sight Medical Products during the 2nd quarter worth about $77,000. Institutional investors own 9.09% of the company’s stock.
About Second Sight Medical Products (Get Rating)
Second Sight Medical Products, Inc develops, manufactures, and markets implantable visual prosthetics that are intended to deliver artificial vision to blind individuals. It develops technologies to treat the population of sight-impaired individuals. The company offers the Orion Visual Cortical Prosthesis System, an implanted cortical stimulation device, which is intended to provide useful artificial vision to individuals who are blind due to various causes, including glaucoma, diabetic retinopathy, optic nerve injury or disease, and eye injury.
- Get a free copy of the StockNews.com research report on Second Sight Medical Products (EYES)
- MarketBeat: Week in Review 5/16 – 5/20
- 3 Retailers That Defied First Quarter Headwinds
- Will John Deere’s Earnings Help to Calm the Markets?
- Rapid7: Could Be Profitable in FY 2022 Despite Bear Market
- Lowe’s Companies Has Not Bottomed
Receive News & Ratings for Second Sight Medical Products Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Second Sight Medical Products and related companies with MarketBeat.com's FREE daily email newsletter.